Open AccessEfficacy and safety of chimeric antigen receptor-T cells in the treatment of B cell lymphoma: a systematic review and meta-analysis
Author(s) -
Xiongwei Zheng,
Xi-You Zhang,
Qianqian Dong,
Feng Chen,
Shuna Yang,
Wenbin Li
Publication year - 2019
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000000568
Subject(s) - medicine , chimeric antigen receptor , cytokine release syndrome , lymphoma , cyclophosphamide , fludarabine , oncology , meta analysis , immunology , chemotherapy , immunotherapy , cancer
Conventional treatment has limited efficacy in relapsed/refractory B-cell lymphoma. Since chimeric antigen receptor T-cell (CAR-T) technology has shown high safety and results in high remission rates, we investigated its efficacy and safety in B-cell lymphoma treatment and analyzed potential affecting factors to provide evidence for therapeutic strategies and applications.